Medicinal products containing hydroxyethyl starch (HES): PRAC confirms its recommendation of suspension of marketing authorisations in the EU
Active substance hydroxyethyl starch, HES
29.06.2018 - CMDh position
The CMDh is introducing new measures in order to protect patients.
22.05.2018 - PRAC recommendation
The PRAC confirms its earlier recommendation for suspension of marketing authorisation.
12.04.2018 - Standing Committee on Medicinal Products for Human Use opinion
The BfArM issues information on the opinion of the Standing Committee for Medicinal Products for Human Use regarding HES within the European safety review in accordance with Article 107i of Directive 2001/83/EC for medicinal products containing HES
26.01.2018 - CMDh position
The Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed the recommendation by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) to suspend the marketing authorisations of medicinal products for infusion containing HES across Europe.
12.01.2018 - PRAC recommendation
In the course of the European safety review according to Article 107i of Directive 2001/83 initiated in October of 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the suspension of marketing authorisations for medicinal products for infusion containing hydroxyethyl starch (HES) in Europe.
27.10.2017 - start of procedure
The BfArM issues information on the initiation of a European safety review according to Article 107i of Directive 2001/83/EC regarding medicinal products containing HES. Studies show low adherence to restrictions aiming at reducing risks of kidney injury and death.
To the risk assessment procedure (available in German only)
For details on the procedure please click on the following link to the homepage of the European Medicines Agency (EMA):